- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07239323
Terapia CAR-T In VIVO para Neoplasias Hematológicas Recurrentes/Refractarias
In Vivo-Generated Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed or Refractory Hematologic Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell(CAR-T cell) therapy in patients with relapsed refractory malignant hematological tumors. Upon enrollment, subjects will receive an intravenous infusion of the in Vivo CAR-T preparation. Following the infusion, subjects will be hospitalized for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Wang Sanbin, PhD
- Número de teléfono: +86 13187424131
- Correo electrónico: sanbin1011@163.com
Ubicaciones de estudio
-
-
Yunnan
-
Kunming, Yunnan, Porcelana
- Reclutamiento
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
-
Contacto:
- Wang Sanbin, PhD
- Número de teléfono: +86 13187424131
- Correo electrónico: sanbin1011@163.com
-
Contacto:
- Sanbin
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age ≥ 18 years old, gender unrestricted;
-
Confirmed diagnosis of relapsed/refractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma;
-
ECOG performance status score 0-2, with an expected survival period of ≥ 3 months;
-
Blood routine test results during the screening period meet the following criteria:
① Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin (rhEPO) is allowed; for patients meeting the hemoglobin ≥ 6 g/dL criterion, red blood cell transfusion can be used to maintain hemoglobin ≥ 6 g/dL;
- Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor [G-CSF] within 1 week before screening, or no use of pegylated G-CSF within 2 weeks before screening); ③ Platelet count ≥ 50,000/μL; ④ Lymphocyte count ≥ 500/μL;
-
Normal renal function during the screening period: creatinine clearance rate (CrCl) ≥ 45 mL/min (calculated using the Cockcroft-Gault formula);
-
Liver function during the screening period meets the following criteria:
① Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3.0 × ULN;
② Total bilirubin (TBIL) ≤ 2.0 × ULN (except for congenital hyperbilirubinemia such as Gilbert's syndrome, direct bilirubin can be relaxed to ≤ 1.5 × ULN);
-
Cardiac function during the screening period meets the following criteria:
① Left ventricular ejection fraction (LVEF) ≥ 40% (measured by echocardiography or MUGA scan);
② No clinically significant pericardial effusion;
③ No clinically significant electrocardiogram (ECG) abnormalities;
-
Pulmonary function during the screening period meets the following criteria: blood oxygen saturation (SpO₂) ≥ 90%;
-
Women of childbearing age must have a negative pregnancy test during the screening period and before drug administration, and must not be in the lactation period;
-
Men and women of childbearing age must agree to take effective contraceptive measures and not donate reproductive cells (including sperm or eggs) from the time of signing the informed consent form until 1 year after the end of study drug administration;
-
The subject or their legally authorized representative has signed the informed consent form (ICF), indicating their understanding of the purpose and procedures of the study and their voluntary participation in this study.
Exclusion Criteria:
-
Other anti-tumor treatments within the screening period (judged by the investigator comprehensively):
① Received chemotherapy, targeted therapy or immunotherapy within 5 half-lives before administration;
② Received radiotherapy within 4 weeks before administration (if the radiotherapy target area covers ≤ 5% of bone marrow reserve, the time limit for radiotherapy completion is not restricted);
-
History of hematopoietic stem cell transplantation: Received allogeneic or autologous hematopoietic stem cell transplantation within 3 months before administration;
-
History of other malignant tumors (except for this disease), except for the following situations:
① Received radical treatment and had no known active disease for ≥ 2 years before enrollment;
② Had fully treated non-melanoma skin cancer in the past and had no active lesions at present;
-
Received treatment related to vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus in the past;
-
Had severe and uncontrolled infections (bacterial, viral, fungal, etc.) within the screening period;
-
Clinically significant cardiac diseases:
-
Had symptomatic heart failure or other serious cardiac diseases (such as severe arrhythmia);
-
Had New York Heart Association (NYHA) Class III-IV congestive heart failure; ③ Had a myocardial infarction or received coronary artery bypass grafting (CABG) / coronary artery stent implantation within 6 months before signing the informed consent;
- Had clinically significant ventricular arrhythmia or a history of unexplained syncope; ⑤ Had a history of syncope (excluding cases caused by vasovagal reactions or dehydration); ⑥ Had a history of severe non-ischemic cardiomyopathy;
-
-
-
Other clinically significant diseases, including but not limited to:
-
Primary immunodeficiency; ② Had a stroke or seizure within 6 months before screening;
- Had clear clinical evidence of dementia or mental status changes; ④ Had Parkinson's disease, Parkinson-like movement disorders or a history of the above;
-
-
Had undergone surgery within 2 weeks before administration, or planned to undergo surgery within 2 weeks after administration (local anesthesia surgery excluded);
-
Had received live attenuated vaccines within 1 month before administration;
-
Had a history of severe allergic reactions to this product or its formulation components;
-
Patients who were not suitable for establishing intravenous access;
-
The investigator believed that there were other conditions that made the patient unsuitable for participating in this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: CAR-T in vivo
|
Patients were enrolled and given a single dose of CAR-T injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 2 years. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximal Tolerated Dose(MTD)
Periodo de tiempo: Up to 28 days after infusion
|
MTD will be determined based on Dose-Limiting Toxicity(DLTs) observed during the first 28 days of study treatment. |
Up to 28 days after infusion
|
|
Incidence of adverse events(AE) after infusion
Periodo de tiempo: Up to 28 days after infusion
|
The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. |
Up to 28 days after infusion
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate
Periodo de tiempo: Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24
|
Objective Response Rate(ORR) is defined as the proportion of subjects achieving complete remission(CR) and partial response(PR). |
Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Wang Sanbin, MD, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades del sistema inmunológico
- Infecciones
- Enfermedades virales
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Infecciones por virus de ADN
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Infecciones por el virus de Epstein-Barr
- Infecciones por herpesviridae
- Infecciones por virus tumorales
- Enfermedades hemic y linfáticas
- Linfoma de células B
- Mieloma múltiple
- Linfoma de Burkitt
Otros números de identificación del estudio
- PBC027-1
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .